Press Releases

(Shanghai, China, November 21, 2024) —WuXi XDC Cayman Inc. (“WuXi XDC”, or the “Company”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is proud to announce that it has been awarded the “Top Investor-Picked Companies” at the 2024 Annual Leading CFO Awards for Hong Kong and U.S. listed companies.

Futu initiated the 2024 Annual Leading CFO Awards, and the selection was based on a comprehensive review, including the companies’ financial information, non-financial disclosure, and experts’ evaluations. This award aims to recognize Hong Kong and U.S. listed companies that proactively communicate with the capital markets, demonstrating transparency and great investment value. To be awarded for this award signifies the capital market’s strong endorsement of WuXi XDC’s business prospects and growth potential, operation efficiency, and strategic foresight.

As a global leader in the ADC CRDMO sector, WuXi XDC was successfully listed on the Stock Exchange of Hong Kong Main Board in November 2023, attracting investments from global top-tier long-only investors, and the IPO was the largest IPO in the Hong Kong Main Board—healthcare sector in 2023, raising more than HK$4 billion. Since the listing, WuXi XDC has effectively communicated its investment value to investors and proactively expanded its global investor base. The company keeps close contact with investors through various channels and media, including earnings press conferences, brokerage meetings, facility site tours, industry conferences, etc. These activities enable us to deliver high-quality updates on business progress and industry trends to the investors, effectively and continuously enhancing investors’ understanding and trust in the Company and fostering recognition of the Company’s investment value.

As of today, the Company has established strong relationships with over 30 onshore and offshore sell-side equity research analysts, all of which have a strong buy rating consensus on the Company. In addition, the Company was included in Hong Kong Stock Connect, Hang Seng Composite Index (“HSCI”), Hang Seng Hong Kong-Listed Biotech Index (“HSHKBIO”), and Hang Seng HK-US Biotech Index (“HSUSB”) quickly after the listing. The Company also received notable Capital Market Awards, including “2023 Best IPO Award” at the China Financial Market Awards by China Finance Magazine, as well as the “Best CEO”, “Best CFO”, and “Best IR Professional” Awards by Institutional Investors in 2023.

Mr. Michael Xi, Chief Financial Officer of WuXi XDC, commented, “As we celebrated the first anniversary since our listing, this award represents not only WuXi XDC’s exceptional efforts in the capital market but also affirms the company’s inherent strengths. Our outstanding results reflect sustainable growth and validate our strategic initiatives. WuXi XDC is a global CRDMO leader in the fast-growing ADC and bioconjugate industry, distinguished by its scale, growth, and scarcity within the stock market, making it a highly differentiated company with a unique investment proposition. Going forward, we are committed to addressing the increasing demand for CRDMO services and accelerating the development and manufacturing of ADCs and XDCs, creating greater value for our shareholders and continuously reinforcing our investor confidence.”

In WuXi XDC’s 2024 interim report, the Company achieved outstanding results, with revenue increased by 67.6% YoY to RMB 1,665 million. Since its establishment until June 30, 2024, the Company has served a total of 419 global clients, and has successfully delivered over 11,000 bioconjugate molecules to date. As of June 30, 2024, WuXi XDC’s funnel encompasses 167 integrated projects, highlighting 29 late-stage projects (clinical phase II and III) and 9 PPQ projects with the potential to submit BLAs in 2024 and beyond.

About WuXi XDC

WuXi XDC Cayman Inc.  (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.
 
WuXi XDC Contacts

Investor：wuxixdc.ir@wuxibiologics.com

Media：wuxixdc_pr@wuxibiologics.com

BD：wuxixdc_info@wuxibiologics.com